By Elizabeth Lopatto
March 25 (Bloomberg) -- Biogen Idec Inc. said it has 20 new medicines in advanced human trials, including treatments for multiple sclerosis, cancer and Parkinson’s disease.
At least six of the new medicines have reached the final tests generally required for U.S. marketing clearance, the Cambridge, Massachusetts-based biotechnology company said today in a statement. Biogen will discuss new medicines it’s developing in a meeting today with investors and analysts in Boston.
Biogen, the world’s largest maker of multiple sclerosis drugs, will have two MS medicines in late-stage trials by the end of this year, including a new version of its top-selling Avonex drug and a pill, called BG-12. Avonex, an injectable medicine, generated $2.2 billion last year, accounting for more than half of Biogen’s $4.1 billion in revenue. Its fastest- growing product is the MS drug Tysabri, which produced worldwide sales of $813 million for Biogen and partner Dublin-based Elan Corp.
Click here to read remainder of this Bloomberg Report.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
0 comments:
Post a Comment